Conference Coverage

Complete Conference Coverage

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Lenvatinib May Delay Functional Deterioration in Hepatocellular Carcinoma

Patients had similar HRQOL scores by all measures at baseline, but experienced significant changes in scores for the HRQOL domains of Body Image, Diarrhea, Nutrition, Pain, and Role Function.

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Eryaspase May Prolong Overall and Progression-free Survival in Pancreatic Cancer

Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

Survival Benefit With Pembrolizumab Confirmed in Urothelial Carcinoma

The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine.

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

Liquid Biopsies Are Highly Sensitive for Actionable Mutations in Solid Tumors

Alterations conferring resistance to targeted agents were identified among 18% of samples from NSCLC, breast, colorectal, and prostate cancers, melanoma, and gastrointestinal stromal tumors.

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

No Difference in Survival With CT Scan at Follow-ups for Resected NSCLC

Although these data did not demonstrate improved survival with the inclusion of a CT scan at routine follow-up visits, the authors noted that a longer follow-up time is necessary to identify any long-term OS benefits.

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Durvalumab May Prolong PFS in Non-small Cell Lung Cancer After Chemoradiation

Researchers randomly assigned 713 patients with NSCLC who did not progress after 2 or more cycles of platinum-based concurrent chemoradiation therapy to receive durvalumab 10 mg/kg consolidation therapy or placebo for up to 12 months.

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

Initial Abemaciclib Improves PFS and ORR in Advanced Breast Cancer

Researchers compared the efficacy of abemaciclib plus anastrozole or letrozole vs placebo plus anastrozole or letrozole among patients not previously treated with a systemic therapy.

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

TILs May Predict Pembrolizumab Response in Triple-negative Breast Cancer

The results of the study demonstrate that increased TIL levels may be associated with a greater response to pembrolizumab monotherapy in patients with mTNBC, especially in the first-line setting.

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Osimertinib Shows Promise As A First-line Therapy in EGFRm NSCLC

Patients who received osimertinib had a PFS of 18.9 months compared with 10.2 months among those who received SoC treatments (P < .0001).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs